Odronextamab Shows Efficacy, Safety in R/R DLBCL After Progression Post–CAR T-Cell Therapy
Pan-Tumor Approvals Stress the Need for Harmonized Testing and Reporting Strategies
Frontline Therapy Selection in HCC Hinges on Bleeding Risk and Patient-Specific Factors
FDA Grants Fast Track Status to SIGX1094 for Diffuse Gastric Cancer